G H Tan1, N Bhoo-Pathy2, N A Taib3, M H See4, S Jamaris5, C H Yip6. 1. Department of Surgery, University Malaya Medical Center, 50603 Kuala Lumpur, Malaysia. Electronic address: giehooi@gmail.com. 2. Department of Social and Preventive Medicine, University Malaya Medical Center, 50603 Kuala Lumpur, Malaysia; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508GA Utrecht, Netherlands. Electronic address: ovenjjay@gmail.com. 3. Department of Surgery, University Malaya Medical Center, 50603 Kuala Lumpur, Malaysia. Electronic address: nuraish@gmail.com. 4. Department of Surgery, University Malaya Medical Center, 50603 Kuala Lumpur, Malaysia. Electronic address: smhoong76@gmail.com. 5. Department of Surgery, University Malaya Medical Center, 50603 Kuala Lumpur, Malaysia. Electronic address: ahshun82@gmail.com. 6. Department of Surgery, University Malaya Medical Center, 50603 Kuala Lumpur, Malaysia. Electronic address: chenghar.yip@gmail.com.
Abstract
INTRODUCTION: Changes in the American Joint Commission on Cancer staging for breast cancer occurred when the 5th Edition was updated to the 6th Edition. OBJECTIVE: To investigate how these changes affected stage and survival. METHODS: 3127 cases of breast cancer were restaged. RESULTS: Late stages increased from 27.7% to 38.1%. The five-year survival improved in Stage 2 (82.9-86.1%) and Stage 3 (50.6-59%). DISCUSSION: Stage shift leads to an erroneous impression that women are presenting with later stages and stage-specific survival is improving. CONCLUSION: Standardizing cancer staging is important when reporting stage and survival in different time periods.
INTRODUCTION: Changes in the American Joint Commission on Cancer staging for breast cancer occurred when the 5th Edition was updated to the 6th Edition. OBJECTIVE: To investigate how these changes affected stage and survival. METHODS: 3127 cases of breast cancer were restaged. RESULTS: Late stages increased from 27.7% to 38.1%. The five-year survival improved in Stage 2 (82.9-86.1%) and Stage 3 (50.6-59%). DISCUSSION: Stage shift leads to an erroneous impression that women are presenting with later stages and stage-specific survival is improving. CONCLUSION: Standardizing cancer staging is important when reporting stage and survival in different time periods.
Authors: Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Jean-Marie Januel; Erik von Elm; Sinéad M Langan Journal: CMAJ Date: 2019-02-25 Impact factor: 8.262
Authors: Mary R Nittala; Eswar K Mundra; S Packianathan; Divyang Mehta; Maria L Smith; William C Woods; Shawn McKinney; Barbara S Craft; Srinivasan Vijayakumar Journal: BMC Cancer Date: 2021-05-17 Impact factor: 4.430
Authors: Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan Journal: Z Evid Fortbild Qual Gesundhwes Date: 2016-09-28
Authors: Cristóbal Maiz; Fernando Silva; Francisco Domínguez; Héctor Galindo; Mauricio Camus; Augusto León; David Oddó; Alejandra Villarroel; Dravna Razmilic; María Elena Navarro; Lidia Medina; Tomás Merino; Eugenio Vines; José Peña; Daniela Maldonado; Mauricio P Pinto; Francisco Acevedo; César Sánchez Journal: Ecancermedicalscience Date: 2020-01-23
Authors: Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan Journal: PLoS Med Date: 2015-10-06 Impact factor: 11.069